The issue with CU64 is not what it’s capable of, it’s the commercial viability due to supply chain issues and significant clinical deployment issues.
Even if clinicians wanted CU 100% of the time you have to get it to them in a cost effective, safe, consistent easy to use way. The benefit and altered patient treatment would have to be substantial vs GA however I don’t believe that to be the case, at least there is no current evidence. LU can pick up small legions to.
Agreed it’s not either or however I can’t see CU taking off given the reasons above.
Cheers
The issue with CU64 is not what it’s capable of, it’s the...
Add TLX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.99 |
Change
0.130(0.57%) |
Mkt cap ! $7.694B | |||
| Open | High | Low | Value | Volume |
| $22.97 | $23.46 | $22.89 | $22.02M | 952.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 3712 | $22.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $23.06 | 540 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| TLX (ASX) Chart |